Abstract Number: 0295 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies
Background/Purpose: Pneumocystis Jirovecii Pneumonia (PJP) is an opportunistic fungal infection with high morbidity and mortality rates. Few studies to date have assessed the incidence of…Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…Abstract Number: 2293 • ACR Convergence 2023
Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We studied whether infections cluster together and which patients are…Abstract Number: 0201 • ACR Convergence 2023
Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months
Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…Abstract Number: 0415 • ACR Convergence 2023
Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort
Background/Purpose: To identify risk of serious infections (SI) according to initial treatment strategy, using conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) and corticosteroids, in patients…Abstract Number: 1297 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in the healthy population. Data on longer-term AEs in people with autoimmune diseases (AIDs), including rheumatoid…Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…Abstract Number: 2298 • ACR Convergence 2023
SLE Patients Are at High Risk for Tuberculosis Infection: Data from a Lupus Center of an Endemic Country
Background/Purpose: SLE patients are at high risk for tuberculosis (TB) infection especially in endemic countries. Despite the importance of this infection condition, there are still…Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…Abstract Number: 0425 • ACR Convergence 2023
Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: Rituximab targets CD20-bearing B cells and is used to treat Rheumatoid Arthritis (RA). Common Variable Immune Deficiency (CVID) is a primary immune deficiency syndrome…Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…Abstract Number: 1801 • ACR Convergence 2023
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 32
- Next Page »